ResearcherJichi Medical UniversityActive in the last 2 years
Giman Jung
Matched on OpenAlex author ID A5111971115. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 4
- Association of apolipoprotein A2 isoform index with demographic, behavioral, and clinical risk factors for pancreatic ductal adenocarcinoma in a single-center … Last author DOI 10.1016/j.ctarc.2026.101328↗
- Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. Co-author DOI 10.1007/s00535-023-02072-w↗
- Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Co-author DOI 10.1038/srep15921↗
- Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Co-author DOI 10.1158/1055-9965.epi-10-0397↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alan H.B. Wu · 1 shared paper, 2026 · strength 0.36
- Michimoto Kobayashi · 3 shared papers, 2011–2024 · strength 0.21
- Paper Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. DOI 10.1007/s00535-023-02072-w↗
- Paper Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibo… DOI 10.1038/srep15921↗
- Paper Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. DOI 10.1158/1055-9965.epi-10-0397↗
- Kazufumi Honda · 3 shared papers, 2011–2024 · strength 0.21
- Paper Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. DOI 10.1007/s00535-023-02072-w↗
- Paper Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibo… DOI 10.1038/srep15921↗
- Paper Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. DOI 10.1158/1055-9965.epi-10-0397↗
- Sudhir Srivastava · 2 shared papers, 2015–2024 · strength 0.19
- Paper Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. DOI 10.1007/s00535-023-02072-w↗
- Paper Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibo… DOI 10.1038/srep15921↗
- Ying Huang · 2 shared papers, 2015–2024 · strength 0.19
- Paper Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. DOI 10.1007/s00535-023-02072-w↗
- Paper Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibo… DOI 10.1038/srep15921↗
- Ayumi Kashiro · 1 shared paper, 2024 · strength 0.15
- Susumu Hijioka · 1 shared paper, 2024 · strength 0.15
- Satoshi Nara · 1 shared paper, 2024 · strength 0.15
- Shingo Kato · 1 shared paper, 2024 · strength 0.15
- Chigusa Morizane · 1 shared paper, 2024 · strength 0.15
- Shoji Nakamori · 2 shared papers, 2011–2015 · strength 0.06
- Tomoo Kosuge · 2 shared papers, 2011–2015 · strength 0.06
- Tatsuya Ioka · 2 shared papers, 2011–2015 · strength 0.06
- Naohiro Sata · 2 shared papers, 2011–2015 · strength 0.06
- Akihiko Tsuchida · 2 shared papers, 2011–2015 · strength 0.06
- Tesshi Yamada · 2 shared papers, 2011–2015 · strength 0.06
- Takuji Okusaka · 2 shared papers, 2011–2015 · strength 0.06
- Hirokazu Shoji · 1 shared paper, 2015 · strength 0.04
- Jo Ann Rinaudo · 1 shared paper, 2015 · strength 0.04
- Tsutomu Chiba · 1 shared paper, 2011 · strength 0.02
- Junichi Matsubara · 1 shared paper, 2011 · strength 0.02
- Yoshinori Tanaka · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.